Feasibility of Gallium-68-tilmanocept PET/CT for Sentinel Lymph Node Detection in Endometrial Cancer

• Status: Not yet recruiting
• Trial end date: 2023-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

This pilot study evaluates the feasibility of 68Ga-tilmanocept PET/CT for SLN mapping in patients with endometrial cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: UMC Utrecht

Criteria

Inclusion Criteria:

• Clinical FIGO 2012 stage I-II high/high-intermediate risk endometrial cancer;

• Scheduled for robot-assisted full pelvic and para-aortic staging;

• Age ≥18 years and able to provide informed consent.

Exclusion Criteria:

• Pregnancy or current breastfeeding;

• Prior severe allergic reaction to iodine;

• Severe renal insufficiency (stage 3 or 4);

• Clinical or radiological evidence of metastatic disease.